Anti-CD38 IgG1 monoclonal antibody that targets CD38 on plasma cells and mediates ADCC, CDC, ADCP, and apoptosis while depleting CD38-positive immunosuppressive cells.
Human IgG1κ monoclonal antibody targeting CD38 on plasma cells; induces direct tumor cell killing via ADCC, CDC, ADCP, and apoptosis, and depletes CD38-positive immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing antitumor immunity.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and triggers immune effector killing—ADCC by NK cells, CDC via complement, ADCP by macrophages—and can also induce apoptosis.
Patient-specific synthetic peptide mixture of tumor neoantigens administered as a vaccine to elicit CD8+ and CD4+ T-cell responses via HLA class I/II presentation.
Patient-specific synthetic neoantigen peptides are taken up by antigen-presenting cells and presented on HLA class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells that recognize and lyse tumor cells expressing those neoantigens and can generate antitumor immune memory.
YES
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells via APC HLA I/II presentation; activated CTLs recognize neoantigen–HLA on tumor cells and kill them via perforin/granzyme-mediated apoptosis (and Fas–FasL).
Patient-specific synthetic peptide mixture of tumor neoantigens administered as a vaccine to elicit CD8+ and CD4+ T-cell responses via HLA class I/II presentation.
Patient-specific synthetic neoantigen peptides are taken up by antigen-presenting cells and presented on HLA class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells that recognize and lyse tumor cells expressing those neoantigens and can generate antitumor immune memory.
NO
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells that recognize neoantigen peptides presented on HLA-A and kill those tumor cells via perforin/granzyme (and Fas) pathways; HLA-A expression alone is not targeted.
Patient-specific synthetic peptide mixture of tumor neoantigens administered as a vaccine to elicit CD8+ and CD4+ T-cell responses via HLA class I/II presentation.
Patient-specific synthetic neoantigen peptides are taken up by antigen-presenting cells and presented on HLA class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells that recognize and lyse tumor cells expressing those neoantigens and can generate antitumor immune memory.
NO
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells that kill tumor cells presenting the neoantigen peptide in complex with HLA class I (e.g., HLA-B) via perforin/granzyme-mediated apoptosis; HLA-B expression alone is not targeted.